Mustang Bio Announces First Patient Treated in Its Multicenter Phase I/II Clinical Trial of MB-106, a First-in-Class CD20-Targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. announced that the first patient has been treated in its multicenter, open-label, non-randomized Phase I/II clinical trial evaluating the safety and efficacy of MB-106, Mustang’s first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.